Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1996 Dec;50(6):667–673. doi: 10.1136/jech.50.6.667

Targeted hepatitis B vaccination--a cost effective immunisation strategy for the UK?

J R Williams 1, D J Nokes 1, R M Anderson 1
PMCID: PMC1060385  PMID: 9039387

Abstract

OBJECTIVE: To compare the potential cost effectiveness of vaccination against hepatitis B virus (HBV) targeted at genitourinary clinic (GU) attendees with that of universal infant vaccination. DESIGN: A mathematical model of sexual and perinatal transmission of HBV was used to compare the effectiveness among heterosexual and homosexual populations of programmes of mass infant vaccination and targeted immunisation of genitourinary medicine (GU) clinic attendees. Each was applied to 90% of the eligible population with differing assumptions about rates of compliance and seroconversion - problems of delivery (obtaining high compliance) was considered a significant drawback of targeted vaccination. Observed relationships between GU clinic attendance and sex partner change rates for heterosexuals and for homosexuals were used to define the rates of vaccination uptake within sexual activity risk groups. SETTING: England and Wales. RESULTS: Model results showed that for heterosexuals universal infant vaccination became more effective than clinic based vaccination only approximately 40 years after the start of the programme and that the predicted cost effectiveness of GU clinic vaccination was greater at all times. For homosexuals, clinic vaccination was always more effective over the time frame considered, but by 50 years if it were carried out without prior screening it had become appreciably less cost effective than a mass infant programme. With prior screening in GU clinics this cost effectiveness deficit was only marginal. CONCLUSIONS: Targeted vaccination might have a much greater potential than is realised at present, particularly if it were possible to improve compliance of clinic attendees. A fuller comparison between mass infant and targeted vaccination must await the specific inclusion in the model of other risk groups such as intravenous drug users. An important determinant of the relative merits of the two approaches is the relationship between rates of attendance and of changing sexual partners. Further research on this is required.

Full text

PDF
667

Images in this article

671Image
on p.671

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. André F. E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990 Mar;8 (Suppl):S74–S80. doi: 10.1016/0264-410x(90)90222-8. [DOI] [PubMed] [Google Scholar]
  2. Bhatti N., Gilson R. J., Beecham M., Williams P., Matthews M. P., Tedder R. S., Weller I. V. Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ. 1991 Jul 13;303(6794):97–101. doi: 10.1136/bmj.303.6794.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brook M. G., Lever A. M., Kelly D., Rutter D., Trompeter R. S., Griffiths P., Thomas H. C. Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med. 1989 Apr;71(264):313–317. [PubMed] [Google Scholar]
  4. Clee W. B., Hunter P. R. Hepatitis B in general practice: epidemiology, clinical and serological features, and control. Br Med J (Clin Res Ed) 1987 Aug 29;295(6597):530–532. doi: 10.1136/bmj.295.6597.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Derso A., Boxall E. H., Tarlow M. J., Flewett T. H. Transmission of HBsAg from mother to infant in four ethnic groups. Br Med J. 1978 Apr 15;1(6118):949–952. doi: 10.1136/bmj.1.6118.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fine P. E. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302. doi: 10.1093/oxfordjournals.epirev.a036121. [DOI] [PubMed] [Google Scholar]
  7. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine. 1990 Mar;8 (Suppl):S129–S138. doi: 10.1016/0264-410x(90)90233-c. [DOI] [PubMed] [Google Scholar]
  8. Jilg W. Selective risk group strategies in Europe. Vaccine. 1995;13 (Suppl 1):S44–S46. doi: 10.1016/0264-410x(95)80049-j. [DOI] [PubMed] [Google Scholar]
  9. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine. 1995;13 (Suppl 1):S16–S17. doi: 10.1016/0264-410x(95)80040-k. [DOI] [PubMed] [Google Scholar]
  10. Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13 (Suppl 1):S47–S49. doi: 10.1016/0264-410x(95)80050-n. [DOI] [PubMed] [Google Scholar]
  11. Kattamis C., Papaevangelou G. Workshop group: Greece. Vaccine. 1995;13 (Suppl 1):S97–S98. doi: 10.1016/0264-410x(95)80071-k. [DOI] [PubMed] [Google Scholar]
  12. Laukamm-Josten U., von Laer G., Feldmeier H., Bienzle U., Uy A., Thomssen R., Guggenmoos-Holzmann I. Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J. 1987;63 (Suppl 2):143–146. [PubMed] [Google Scholar]
  13. Mangtani P., Hall A. J., Normand C. E. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health. 1995 Jun;49(3):238–244. doi: 10.1136/jech.49.3.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roure C. Congress objectives. Vaccine. 1995;13 (Suppl 1):S9–10. doi: 10.1016/0264-410x(95)80036-d. [DOI] [PubMed] [Google Scholar]
  15. Roure C. Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine. 1995;13 (Suppl 1):S18–S21. doi: 10.1016/0264-410x(95)80041-b. [DOI] [PubMed] [Google Scholar]
  16. Wheeley S. M., Tarlow M. J., Boxall E. H. Chronic hepatitis B in male and female children of HBsAg carrier mothers. J Hepatol. 1989 Mar;8(2):226–231. doi: 10.1016/0168-8278(89)90011-1. [DOI] [PubMed] [Google Scholar]
  17. Williams J. R., Nokes D. J., Medley G. F., Anderson R. M. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 Feb;116(1):71–89. doi: 10.1017/s0950268800058970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. el-Dalil A., Radcliffe K. W., Bailey J., Richmond R. A., Wade A. A. A survey on hepatitis B vaccination policies in genitourinary medicine in UK and Ireland. Genitourin Med. 1995 Aug;71(4):251–253. doi: 10.1136/sti.71.4.251. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES